Brief: Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic And Safety Data For Imm-1-104 Universal-Ras Program Accelerates Study Timeline

Immuneering

18/04/2023 14:02

April 18 (Reuters) - Immuneering Corp  IMRX.O :
    * IMMUNEERING ANNOUNCES POSITIVE INITIAL PHASE 1
PHARMACOKINETIC,
PHARMACODYNAMIC AND SAFETY DATA FOR IMM-1-104 UNIVERSAL-RAS
PROGRAM; ACCELERATES STUDY TIMELINE
    * IMMUNEERING CORP - IMM-1-104 WELL TOLERATED WITH NO DOSE
LIMITING TOXICITIES (DLTS) OR SERIOUS ADVERSE EVENTS (SAES)
OBSERVED
    * IMMUNEERING CORP - IMM-1-104 WELL TOLERATED WITH NO DOSE
LIMITING TOXICITIES (DLTS) OR SERIOUS ADVERSE EVENTS (SAES)
OBSERVED
    * IMMUNEERING CORP - PHARMACODYNAMIC DATA SUPPORT POTENTIAL
TO
EVALUATE PRELIMINARY EFFICACY SOONER THAN EXPECTED
    * IMMUNEERING CORP - PHARMACODYNAMIC DATA SUPPORT POTENTIAL
TO
EVALUATE PRELIMINARY EFFICACY SOONER THAN EXPECTED
    * IMMUNEERING CORP - RECOMMENDED PHASE 2 DOSE (RP2D) NOW
EXPECTED
IN EARLY 2024
    * IMMUNEERING CORP - STUDY TIMELINE ACCELERATED: RECOMMENDED
PHASE
2 DOSE (RP2D) NOW EXPECTED IN EARLY 2024

Source text for Eikon:  ID:nGNXbB6zCn 
Further company coverage:  IMRX.O